Starting with Micro Perspectives and Leading with Innovation

Yantai Lannacheng Biotech Co., Ltd. was established in early 2021, with its headquarters in Yantai, China, and a subsidiary in Singapore. Founded by Dongcheng Pharmaceutical Group, a leading enterprise with significant influence in China’s nuclear medicine sector, Lannacheng is dedicated to the research, development, and registration of first-in-class innovative radiopharmaceuticals integrating diagnosis and therapy. The company is developing various theranostic radiopharmaceutical pipelines with strong translational potential, serving as a core part of Dongcheng’s nuclear medicine ecosystem.

Lannacheng has established a pipeline comprising 13 drug candidates, including seven diagnostic radiopharmaceuticals and six therapeutic radiopharmaceuticals. The company’s R&D engine integrates key capabilities such as target validation, radioisotope selection, and linker design, and is further strengthened by its proprietary pharmacokinetic optimization technologies and dual-target drug development platform. In parallel, the company has commenced construction of a new manufacturing facility in Yantai, Shandong Province, covering approximately 4,886 square meters. The facility is designed in compliance with stringent cGMP standards and is expected to be completed by the first quarter of 2026. This initiative aims to enhance the company’s end-to-end operational capabilities from manufacturing to commercialization and establish a closed-loop system for radiopharmaceutical R&D and industrialization.